Financhill
Back

Nuvectis Pharma Quote, Financials, Valuation and Earnings

Nuvectis Pharma Price Quote

$4.68
-0.02 (0.86%)
(Updated: December 14, 2024 at 4:21 AM ET)

Nuvectis Pharma Key Stats

Sell
11
Nuvectis Pharma (NVCT) is a Sell

Day range:
$4.53 - $4.86
52-week range:
$4.52 - $12.10
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
8.16%

Volume:
102.7K
Avg. volume:
221K
1-year change:
-44.58%
Market cap:
$89.6M
Revenue:
$0
EPS:
$-1.16

How Much Does Nuvectis Pharma Make?

Data Unavailable

Is Nuvectis Pharma Growing As A Company?

Data Unavailable

Nuvectis Pharma Stock Price Performance

  • Did Nuvectis Pharma Stock Go Up Last Month?
    Nuvectis Pharma share price went down by -55.95% last month
  • Did NVCT's Share Price Rise Over The Last Year?
    NVCT share price fell by -44.58% over the past 1 year

What Is Nuvectis Pharma 52-Week High & Low?

Nuvectis Pharma Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Nuvectis Pharma?

  • How Much Debt Does Nuvectis Pharma Have?
    Total long term debt quarterly is $0
  • How Much Cash Does Nuvectis Pharma Have?
    Cash and short term investments quarterly total is $17.2M
  • What Is Nuvectis Pharma’s Book Value Per Share?
    Book value per share is 0.58

Is Nuvectis Pharma Cash Flow Positive?

  • What Is NVCT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$13.6M
  • What Is Nuvectis Pharma’s Cash Flow From Financing?
    Cash flow from financing (TTM) is $8.7M
  • What Is Nuvectis Pharma’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $0

Nuvectis Pharma Return On Invested Capital

Data Unavailable

Nuvectis Pharma Earnings Date & Stock Price

Nuvectis Pharma Competitors

  • Who Are Nuvectis Pharma's Competitors?
    Below is a list of companies who compete with Nuvectis Pharma or are related in some way:
    • AIM ImmunoTech Inc (AIM)
    • Calidi Biotherapeutics Inc (CLDI)
    • CEL-SCI Corp (CVM)
    • Harrow Inc (HROW)
    • IGC Pharma Inc (IGC)

Nuvectis Pharma Dividend Yield

Nuvectis Pharma Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 0%
Revenue: 0% 0%

Analyst Recommendations

Buy Recommendations: 1
Hold Recommendations: 0
Sell Recommendations: 0
Price Target: 22.00
Upside from Last Price: 368.09%

Major Shareholders

  • How many NVCT shares are owned by institutional investors?
    1.6M NVCT shares are owned by institutional investors
  • How many NVCT shares are owned by insiders?
    6.6M NVCT shares are owned by insiders